Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 22
163
Views
9
CrossRef citations to date
0
Altmetric
Research Articles

Cytotoxicity of a new tirucallane derivative isolated from Stereospermum acuminatissimum K. Schum stem bark

, , , , , , , & show all
Pages 4417-4422 | Received 03 Oct 2019, Accepted 20 Jan 2020, Published online: 03 Feb 2020
 

Abstract

One new tirucallan derivative, leutcharic acid (1) was isolated from Stereospermum acuminatissimum stem bark together with the known compounds 3-oxo-22-hydroxyhopane (2), 3,4-secotirucalla-4(28),7,24-trien-3,21-dioic acid (3), 3-oxotirucalla-7,24-dien-21-oic acid (7), lupeol (4), β-sitosterol (5) and stigmasterol (6). The structures of the isolated compounds were elucidated using 1 D and 2 D NMR spectroscopy in combination with literature data. To the best of our knowledge, this is the first report on the cytotoxic properties’ constituents of S. acuminatissimum. Cytotoxicity of compounds 1 and 2 was assessed in vitro with the WST-1 assay on human lung adenocarcinoma A549 and THP-1 human monocytic leukaemia cell lines. Both compounds showed antiproliferative activity on the cancer cells. Compound 2 was more active against THP-1 with an IC50 value of 26.83 µM. The sensitivity of THP-1 cells to compounds 1 and 2 indicated that these compounds might be potential leads for anticancer agent development against leukaemia.

Graphical Abstract

Acknowledgements

AML and DKS would like to thank Alexander von Humboldt-Stiftung for support through Georg Forster Fellowship for Experienced Researchers re-invitation (ID N° 1137675) at the University of Bielefeld (Germany). The biological part of this work was supported by the Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne. Grateful acknowledgment is also made to the Swiss National Foundation for providing financial support to JPD through the project n° IZSEZO_180383/1.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.